Literature DB >> 30595535

AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness.

Xinbo Wang1, Jiali Jin2, Fangning Wan3, Linlin Zhao2, Hongshang Chu4, Cong Chen4, Guanghong Liao4, Jian Liu5, Yue Yu4, Hongqi Teng6, Lan Fang6, Cong Jiang4, Weijuan Pan4, Xin Xie5, Jia Li5, Xiaolin Lu3, Xuejun Jiang7, Xin Ge8, Dingwei Ye9, Ping Wang10.   

Abstract

NANOG is an essential transcriptional factor for the maintenance of embryonic stem cells (ESCs) and cancer stem cells (CSCs) in prostate cancer (PCa). However, the regulation mechanism of NANOG protein stability in cancer progression is still elusive. Here, we report that NANOG is degraded by SPOP, a frequently mutated tumor suppressor of PCa. Cancer-associated mutations of SPOP or the mutation of NANOG at S68Y abrogates the SPOP-mediated NANOG degradation, leading to elevated PCa cancer stemness and poor prognosis. In addition, SPOP-mediated NANOG degradation is controlled by the AMPK-BRAF signal axis through the phosphorylation of NANOG at Ser68, which blocked the interaction between SPOP and NANOG. Thus, our study provides a regulation mechanism of PCa stemness controlled by phosphorylation-mediated NANOG stability, which helps to identify novel drug targets and improve therapeutic strategy for PCa.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK-BRAF axis; NANOG; SPOP; prostate cancer stem cell; ubiquitination

Mesh:

Substances:

Year:  2018        PMID: 30595535     DOI: 10.1016/j.devcel.2018.11.033

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  28 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 3.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

4.  Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.

Authors:  Alicia Bort; Belén G Sánchez; Irene de Miguel; Pedro A Mateos-Gómez; Inés Diaz-Laviada
Journal:  Mol Biol Rep       Date:  2020-03-03       Impact factor: 2.316

Review 5.  AMPK's double-faced role in advanced stages of prostate cancer.

Authors:  Faeze Gharibpoor; Sara Kamali Zonouzi; Sepideh Razi; Nima Rezaei
Journal:  Clin Transl Oncol       Date:  2022-07-04       Impact factor: 3.340

6.  TNFAIP3 promotes ALDH-positive breast cancer stem cells through FGFR1/MEK/ERK pathway.

Authors:  Wanru Feng; Mengdi Gao; Mao Yang; Xue Li; Zhonglin Gan; Ting Wu; Yan Lin; Tao He
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 7.  Kelch-like proteins in the gastrointestinal tumors.

Authors:  An-Bo Fu; Sen-Feng Xiang; Qiao-Jun He; Mei-Dan Ying
Journal:  Acta Pharmacol Sin       Date:  2022-10-20       Impact factor: 7.169

Review 8.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

9.  EMT and Cancer Cell Stemness Associated With Chemotherapeutic Resistance in Esophageal Cancer.

Authors:  Xiaojie Liu; Mingjing He; Linlin Li; Xiya Wang; Shuhua Han; Jinzhu Zhao; Yalong Dong; Mushtaq Ahmad; Leilei Li; Xueyan Zhang; Junfeng Huo; Yunfan Liu; Chengxue Pan; Cong Wang
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

10.  PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.

Authors:  Fengchao Liu; Xiaoling Wu; Yanzhi Qian; Xin Jiang; Yiying Wang; Jian Gao
Journal:  Cell Death Dis       Date:  2020-06-08       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.